Progen Industries to Conduct Phase I Trial of PI-88 and Docetaxel

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

BRISBANE, Australia-Progen Industries is conducting a phase I trial combining its cancer drug PI-88 with docetaxel (Taxotere) in patients with advanced malignancies. The trial is taking place at the University of Colorado Cancer Center,

BRISBANE, Australia—Progen Industries is conducting a phase I trial combining its cancer drug PI-88 with docetaxel (Taxotere) in patients with advanced malignancies. The trial is taking place at the University of Colorado Cancer Center, Denver, with Scott Holden, MD, as principal investigator, Progen said in a news release.

PI-88 is a semisynthetic sulfated oligosaccharide that has several modes of action. In animal models it has been shown to prevent angiogenesis by inhibiting fibroblast growth factor, and to block metastasis by inhibiting the enzyme heparinase, which allows cancer cells to escape blood vessels. It also stimulates sustained release of TFPI (tissue factor pathway inhibitor), a natural inhibitor of angiogenesis, from cells lining the blood vessel wall.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content